Since the outbreak of Coronavirus Disease 2019 (COVID-19) in December 2019, many studies have reported the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the conjunctival sac of patients infected with this virus, with several patients displaying symptoms of viral conjunctivitis. However, to our best knowledge, there is no in-depth report on the course of patients with COVID-19 complicated by relapsing viral conjunctivitis or keratoconjunctivitis. A 53-year-old man confirmed with COVID-19 developed symptoms of viral conjunctivitis in the left eye approximately 10 days after the onset of COVID-19. The results of a nucleic acid test were positive for SARS-CoV-2 in the conjunctival sac of the left eye. The symptoms were relieved 6 days after treatment. However, the patient was subsequently diagnosed with viral keratoconjunctivitis in both eyes 5 days after the symptoms in the left eye were satisfactorily relieved. The disease progressed rapidly, with spot staining observed at the periphery of the corneal epithelium. Although SARS-CoV-2 could not be detected in conjunctival secretions, the levels of inflammatory factors, such as interleukin-6, were increased in both eyes. Both eyes were treated with glucocorticoids, and symptoms were controlled within 5 days. There was no recurrence. In this case report, the pathogenesis, clinical manifestations, treatment, and outcome of a case with COVID-19 complicated by relapsing viral keratoconjunctivitis is described, and the involvement of topical cytokine surge in the pathogenesis of COVID-19 as it relates to viral keratoconjunctivitis is reported.

中文翻译：

---

COVID-19 中的复发性病毒性角结膜炎：病例报告。

自 2019 年 12 月爆发 2019 冠状病毒病（COVID-19）以来，许多研究报告感染该病毒的患者的结膜囊中存在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），其中几名患者表现出病毒性结膜炎的症状。然而，据我们所知，尚无关于COVID-19并发复发性病毒性结膜炎或角结膜炎患者病程的深入报道。一名被确诊感染 COVID-19 的 53 岁男子在感染 COVID-19 后约 10 天出现左眼病毒性结膜炎症状。左眼结膜囊核酸检测结果为SARS-CoV-2阳性。治疗6天后症状缓解。然而，在左眼症状得到满意缓解5天后，患者随后被诊断为双眼患有病毒性角结膜炎。疾病进展迅速，在角膜上皮周边观察到斑点染色。尽管在结膜分泌物中无法检测到 SARS-CoV-2，但双眼中白细胞介素 6 等炎症因子的水平有所增加。双眼均接受糖皮质激素治疗，症状在5天内得到控制。没有复发。本病例报告描述了 1 例 COVID-19 并发复发性病毒性角结膜炎病例的发病机制、临床表现、治疗和结果，以及局部细胞因子激增在 COVID-19 发病机制中的作用，因为它与病毒性角结膜炎有关被报道。